Stay up to date with the latest news, insights, and updates from Tixel.
11 items
Hear expert insights from Dr. April Jasper from Advanced Eye Care Specialists in South Florida and Dr. Lauren Bailey at West Plano Dry Eye and Aesthetics as they break down dry eye and its most common cause — Meibomian Gland Dysfunction (MGD).
Inside the Blueprint on Fox Business and Bloomberg TV features a revolutionary dry eye treatment: Tixel by Novoxel Inc. FDA-cleared and backed by clinical research, Tixel i® delivers localized heat and pressure therapy to treat evaporative dry eye from MGD—with both eyes treated in just 2 minutes, radiation-free.
In a recent USA today, Dr. Arthur Benjamin of the Benjamin Eye Institute highlights the benefits of treating dry eye before laser or cataract surgery.
Following the U.S. Food and Drug Administration’s recent safety warning regarding radiofrequency (RF) microneedling devices, Novoxel, the manufacturer of Tixel, is reaffirming the distinct safety and technology advantages of its proprietary Thermo-Mechanical Action (TMA) technology.
A recent study published in JOJ Ophthalmology confirms that Novoxel’s FDA-cleared Tixel i® device delivers long-lasting improvements for patients with evaporative dry eye disease caused by Meibomian Gland Dysfunction (MGD). The non-invasive treatment significantly enhanced clinical measures like Tear Break-Up Time and Meibomian Gland Scores, while reducing Ocular Surface Disease Index scores—all without adverse effects. Real-world results at West Plano Dry Eye & Aesthetics echoed the findings, with patients reporting meaningful symptom relief in under two minutes per session. Dr. Lauren Bailey praised Tixel i® as a breakthrough for patients who had exhausted other options.
Dr. Noaman Sanni of Center for Sight New York has experienced significant patient and revenue growth after integrating Tixel i®, Novoxel’s FDA-cleared device for Meibomian Gland Dysfunction (MGD), into his practice. Within two months, over 225 patients received the quick, non-invasive treatment, which delivers lasting relief in under two minutes without the need for anesthesia or consumables. Dr. Debra Koloms, the clinic’s medical director, praised Tixel i® as “the most impressive treatment” she has encountered in 40 years of practice.
Novoxel Inc. and GPOphtho have announced a strategic partnership to bring Novoxel’s FDA-cleared Tixel® devices, including the rapid, non-invasive Tixel i® for dry eye and aesthetic treatments, to eyecare providers nationwide—offering discounted pricing and innovative, consumable-free technology.
In this recent USA Today spotlight, learn how Tixel’s innovative 2-minute treatment is offering long-lasting relief for dry eye sufferers—and why eye care practices across the country are rapidly adopting it. From patient success stories to clinical insights, this feature explores the science and simplicity behind Tixel’s impact..
USA Today highlights the breakthrough treatment that's changing lives for millions suffering from dry eye disease. Featured doctors and real patients share their remarkable results.
Following the U.S. Food and Drug Administration’s recent safety warning regarding RF microneedling devices, Novoxel reaffirms the distinct safety and technology advantages of Tixel’s proprietary Thermo-Mechanical Action (TMA) technology.
